These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
717 related articles for article (PubMed ID: 22284039)
1. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report. Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741 [TBL] [Abstract][Full Text] [Related]
3. Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer. Lilleby W; Tafjord G; Raabe NK Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):933-9. PubMed ID: 22138456 [TBL] [Abstract][Full Text] [Related]
4. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Demanes DJ; Brandt D; Schour L; Hill DR Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902 [TBL] [Abstract][Full Text] [Related]
5. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980 [TBL] [Abstract][Full Text] [Related]
6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838 [TBL] [Abstract][Full Text] [Related]
7. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182 [TBL] [Abstract][Full Text] [Related]
8. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788 [TBL] [Abstract][Full Text] [Related]
9. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study. Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768 [TBL] [Abstract][Full Text] [Related]
10. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471 [TBL] [Abstract][Full Text] [Related]
11. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation. Vicini FA; Kestin LL; Martinez AA Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815 [TBL] [Abstract][Full Text] [Related]
12. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244 [TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839 [TBL] [Abstract][Full Text] [Related]
15. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040 [TBL] [Abstract][Full Text] [Related]
16. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999 [TBL] [Abstract][Full Text] [Related]
17. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer. Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486 [TBL] [Abstract][Full Text] [Related]
18. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237 [TBL] [Abstract][Full Text] [Related]
19. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer. Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851 [TBL] [Abstract][Full Text] [Related]
20. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]